These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 23347690)

  • 21. Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection.
    Makobongo MO; Keegan B; Long CA; Miller LH
    J Infect Dis; 2006 Mar; 193(5):731-40. PubMed ID: 16453270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1 alpha domain.
    Moll K; Pettersson F; Vogt AM; Jonsson C; Rasti N; Ahuja S; Spångberg M; Mercereau-Puijalon O; Arnot DE; Wahlgren M; Chen Q
    Infect Immun; 2007 Jan; 75(1):211-9. PubMed ID: 17074852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquisition of naturally occurring antibody responses to recombinant protein domains of Plasmodium falciparum erythrocyte membrane protein 1.
    Mackintosh CL; Christodoulou Z; Mwangi TW; Kortok M; Pinches R; Williams TN; Marsh K; Newbold CI
    Malar J; 2008 Aug; 7():155. PubMed ID: 18706102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of strain-transcending antibodies against Group A PfEMP1 surface antigens from virulent malaria parasites.
    Ghumra A; Semblat JP; Ataide R; Kifude C; Adams Y; Claessens A; Anong DN; Bull PC; Fennell C; Arman M; Amambua-Ngwa A; Walther M; Conway DJ; Kassambara L; Doumbo OK; Raza A; Rowe JA
    PLoS Pathog; 2012; 8(4):e1002665. PubMed ID: 22532802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of drug-loaded immunoliposomes for the selective targeting and elimination of rosetting Plasmodium falciparum-infected red blood cells.
    Moles E; Moll K; Ch'ng JH; Parini P; Wahlgren M; Fernàndez-Busquets X
    J Control Release; 2016 Nov; 241():57-67. PubMed ID: 27620073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of naturally acquired, strain-transcending antibodies against rosetting
    McLean FE; Azasi Y; Sutherland C; Toboh E; Ansong D; Agbenyega T; Awandare G; Rowe JA
    Infect Immun; 2024 Jul; 92(7):e0001524. PubMed ID: 38842304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An in vivo and in vitro model of Plasmodium falciparum rosetting and autoagglutination mediated by varO, a group A var gene encoding a frequent serotype.
    Vigan-Womas I; Guillotte M; Le Scanf C; Igonet S; Petres S; Juillerat A; Badaut C; Nato F; Schneider A; Lavergne A; Contamin H; Tall A; Baril L; Bentley GA; Mercereau-Puijalon O
    Infect Immun; 2008 Dec; 76(12):5565-80. PubMed ID: 18809668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rosetting Plasmodium falciparum-infected erythrocytes bind to human brain microvascular endothelial cells in vitro, demonstrating a dual adhesion phenotype mediated by distinct P. falciparum erythrocyte membrane protein 1 domains.
    Adams Y; Kuhnrae P; Higgins MK; Ghumra A; Rowe JA
    Infect Immun; 2014 Mar; 82(3):949-59. PubMed ID: 24343658
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of the antibody response against Plasmodium falciparum erythrocyte membrane protein 1 in human volunteers.
    Krause DR; Gatton ML; Frankland S; Eisen DP; Good MF; Tilley L; Cheng Q
    Infect Immun; 2007 Dec; 75(12):5967-73. PubMed ID: 17923524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure of a Plasmodium falciparum PfEMP1 rosetting domain reveals a role for the N-terminal segment in heparin-mediated rosette inhibition.
    Juillerat A; Lewit-Bentley A; Guillotte M; Gangnard S; Hessel A; Baron B; Vigan-Womas I; England P; Mercereau-Puijalon O; Bentley GA
    Proc Natl Acad Sci U S A; 2011 Mar; 108(13):5243-8. PubMed ID: 21402930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive analysis of Fc-mediated IgM binding to the Plasmodium falciparum erythrocyte membrane protein 1 family in three parasite clones.
    Quintana MDP; Ecklu-Mensah G; Tcherniuk SO; Ditlev SB; Oleinikov AV; Hviid L; Lopez-Perez M
    Sci Rep; 2019 Apr; 9(1):6050. PubMed ID: 30988351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies to Escherichia coli-expressed C-terminal domains of Plasmodium falciparum variant surface antigen 2-chondroitin sulfate A (VAR2CSA) inhibit binding of CSA-adherent parasites to placental tissue.
    Saveria T; Oleinikov AV; Wiliamson K; Chaturvedi R; Lograsso J; Keitany GJ; Fried M; Duffy P
    Infect Immun; 2013 Apr; 81(4):1031-9. PubMed ID: 23319559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of synthetic peptide constructs based on PvMSP9
    Rodrigues-da-Silva RN; Correa-Moreira D; Soares IF; de-Luca PM; Totino PRR; Morgado FN; Oliveira Henriques MDG; Peixoto Candea AL; Singh B; Galinski MR; Moreno A; Oliveira-Ferreira J; Lima-Junior JDC
    Vaccine; 2019 Jan; 37(2):306-313. PubMed ID: 30509693
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
    Hui GS; Nikaido C; Hashiro C; Kaslow DC; Collins WE
    Infect Immun; 1996 May; 64(5):1502-9. PubMed ID: 8613353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
    Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
    Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Id1-DBL2X of VAR2CSA as a key domain inducing highly inhibitory and cross-reactive antibodies.
    Bordbar B; Tuikue-Ndam N; Bigey P; Doritchamou J; Scherman D; Deloron P
    Vaccine; 2012 Feb; 30(7):1343-8. PubMed ID: 22226864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple antigen peptide vaccines against Plasmodium falciparum malaria.
    Mahajan B; Berzofsky JA; Boykins RA; Majam V; Zheng H; Chattopadhyay R; de la Vega P; Moch JK; Haynes JD; Belyakov IM; Nakhasi HL; Kumar S
    Infect Immun; 2010 Nov; 78(11):4613-24. PubMed ID: 20823210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of crossreactive antibodies against the Plasmodium falciparum variant protein.
    Gratepanche S; Gamain B; Smith JD; Robinson BA; Saul A; Miller LH
    Proc Natl Acad Sci U S A; 2003 Oct; 100(22):13007-12. PubMed ID: 14569009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.